412 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
BIIB Biogen Inc. $334.44 $67.37B Downtrend
Article Searches
3 Tech Stocks for Growth Investors to Buy Right Now http://www.zacks.com/stock/news/418127/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-ZC-FT-418127 May 22, 2019 - Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.
Top Research Reports for Chubb, Las Vegas Sands & Biogen http://www.zacks.com/research-daily/417878/top-research-reports-for-chubb-las-vegas-sands-biogen?cid=CS-ZC-FT-417878 May 22, 2019 - Top Research Reports for Chubb, Las Vegas Sands & Biogen
Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN http://www.zacks.com/stock/news/418103/biotech-stock-roundup-label-expansion-for-celgs-drugs-setback-for-imgn?cid=CS-ZC-FT-418103 May 22, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid http://www.zacks.com/stock/news/416133/celgene-gets-ec-nod-for-label-expansion-of-revlimid-imnovid?cid=CS-ZC-FT-416133 May 17, 2019 - Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.
5 Low Price-to-Book Value Stocks for Great Returns http://www.zacks.com/stock/news/414242/5-low-price-to-book-value-stocks-for-great-returns?cid=CS-ZC-FT-414242 May 15, 2019 - P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
What's in the Cards for Sunesis (SNSS) This Earnings Season? http://www.zacks.com/stock/news/406478/whats-in-the-cards-for-sunesis-snss-this-earnings-season?cid=CS-ZC-FT-406478 May 01, 2019 - Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates http://www.zacks.com/stock/news/406790/biotech-stock-roundup-biib-vrtx-alxn-q1-earnings-top-other-pipeline-updates?cid=CS-ZC-FT-406790 May 01, 2019 - Key highlights of the past week are earnings releases by most leading biotech entities.
3 Tech Stocks for Growth Investors to Buy Right Now http://www.zacks.com/stock/news/406067/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-ZC-FT-406067 Apr 30, 2019 - Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...
Is This Highly-Anticipated Gene Therapy in Trouble? https://www.fool.com/investing/2019/04/26/is-this-highly-anticipated-gene-therapy-in-trouble.aspx?source=iedfolrf0000001 Apr 26, 2019 - A patient death raises questions ahead of a key FDA decision next month.
Biogen Looks to 23 Clinical Programs for Growth https://www.fool.com/investing/2019/04/25/biogen-looks-to-23-clinical-programs-for-growth.aspx?source=iedfolrf0000001 Apr 25, 2019 - First-quarter sales were up 11%, but future growth is less certain.

Pages: 123456...42

Page 1>